Regulatory status explainer

Retatrutide approval status: where the trials actually are

By the Decadewise team Education only Last updated 10 August 2026 Agency and registry records

Short answer

The compound: retatrutide, development code LY3437943, is an investigational agonist at the GIP, GLP-1 and glucagon receptors. It holds no marketing approval anywhere we could check.

The status on 9 August 2026: a query of the Drugs@FDA database for retatrutide as an active ingredient returns no matches. The same query for tirzepatide returns two applications, which is how we know the query works.

What the sponsor has filed: nothing yet. Its second-quarter report to the SEC says the clinical package is complete and that it plans to submit a Biologics License Application in the first quarter of 2027.

What the agency has published: retatrutide cannot be used in compounding under federal law, and a March 2026 warning letter calls a marketed version an unapproved new drug.

The one open route: a single-patient expanded access record, posted June 2026.

On this page

Short answer What FDA's record returns What has not happened yet The phase 3 program Is it FDA approved? Is there a lawful route? Why is it in FDA databases? Is every registry entry real? What is unsettled The safety picture How this is sourced Related pages The disclaimer

What does FDA's own record return for retatrutide?

Six queries, run and recorded: each row below names the federal system, the exact query put to it on 9 August 2026, and the answer it gave back. None of it is a summary of a summary.

Six queries, six answers, one date

System	Query	What came back
Drugs@FDA, the approvals database	active ingredient RETATRUTIDE	no matches
Drugs@FDA, the same field	active ingredient TIRZEPATIDE, run as a control	two applications, NDA 215866 and NDA 217806
FDA drug labeling	substance name RETATRUTIDE	no matches
National Drug Code directory	active ingredient RETATRUTIDE	twelve entries, every one filed as a bulk ingredient with an empty application number
DailyMed	drug name retatrutide	ten structured product labels, all from one labeler, all published 17 November 2025
ClinicalTrials.gov	intervention retatrutide	thirty-three records

The control row exists because an empty result proves nothing on its own. A search that finds no approval and a search that is broken look identical from the outside.

The distinction those rows turn on: approved, listed and registered are three different states, and only the first one involves the agency deciding that a product does what its label says. The other two are filings that a company makes.

What has not happened yet, in order

The sequence an approval requires: a sponsor assembles a package, the sponsor submits it, the agency reviews it, and the agency decides. Retatrutide has not reached step two.

Done, per the sponsor's own filings

The clinical package: its second-quarter 2026 report states the data package is complete to support global registrations for obesity, obstructive sleep apnea and knee osteoarthritis pain.

The endpoints: its quarterly report to the SEC records that phase 3 obesity trials met their primary endpoints and that a phase 3 diabetes trial met its primary endpoint.

Not done

The submission: the same report gives a plan to file in the first quarter of 2027. A plan to file is not a filing, and a filing is not an approval.

Everything downstream: no review clock, no advisory committee, no action date, and no label. A label is the document that would settle what the product is for and who it excludes, and there is none to read.

Why the pathway itself is worth noticing: the sponsor says it intends a Biologics License Application rather than a New Drug Application. Which of the two a molecule travels under is the agency's call, and nothing in the documents we pulled records that call being made.

The registered program

What the register holds, phase by phase

The shape of the register: thirty-three records answer an intervention search for retatrutide. Fourteen are phase 1, four are phase 2, fourteen are phase 3, and one is an expanded access entry. Thirty-two name Eli Lilly and Company as sponsor.

The fourteen phase 3 records, by status

Group	Records	What the registry lists
completed	5	TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4, and the diabetes monotherapy trial NCT06354660
active, not recruiting	8	includes TRIUMPH-5 through TRIUMPH-9, a head-to-head against semaglutide, and a cardiovascular and kidney outcomes trial planning 10,000 participants
recruiting	1	a master protocol in metabolic dysfunction-associated steatohepatitis, listing completion in August 2032
combined enrollment	25,364 participants across the fourteen phase 3 records, counting planned and actual figures together

Counted from the ClinicalTrials.gov version 2 API on 9 August 2026. Status labels are the registry's own.

The design, from the program's own paper: TRIUMPH is four phase 3 randomized double-blind studies in over 5,800 participants, built as a basket. TRIUMPH-1 and TRIUMPH-2 are weight management trials with sleep apnea and osteoarthritis protocols nested inside them, TRIUMPH-3 runs in a population with cardiovascular disease, and TRIUMPH-4 is a standalone osteoarthritis trial.

The one phase 3 result in the literature so far: TRANSCEND-T2D-1, a 40-week trial at 48 sites in the United States, Mexico and India, randomized 537 adults with type 2 diabetes to three retatrutide groups or placebo. The primary endpoint was change in HbA1c at week 40, and all three groups separated from placebo. It is registered as NCT06354660.

A naming trap worth knowing before you search: the registry prints TRIUMPH-1 through TRIUMPH-9 as acronyms on the obesity records, and prints no acronym at all on the diabetes and kidney trials. The TRANSCEND names those trials carry in the journals appear nowhere in the registry fields, so searching the register for TRANSCEND finds none of them.

Is retatrutide FDA approved?

No, and not in any partial or conditional sense either. There is no approved product, no application under review that the agency has announced, and no label of the kind an approved peptide carries. The compound sits at the stage where its evidence exists and its paperwork does not.

The confusion this question usually carries: two molecules from the same sponsor and the same drug class already are approved, which makes a third feel like a formality. Approval does not run in families. It is granted to one product, at one strength, for one population, and the approved sibling's own record is evidence about that sibling and nothing else.

Is there a lawful route to it before approval?

One, and it is narrow. The sponsor posted a pre-approval expanded access record on 5 June 2026, updated 6 August 2026, listing its status as available. It is single-patient access, which means a treating physician requests it for one named individual rather than a person signing up.

What the expanded access record requires, all of it

Criterion	As the record states it
age	18 years or older
severity	refractory obesity, defined as a body mass index of 35 or more despite adherence to and tolerance of the highest available dose of chronic weight management therapy
complications	two or more serious or life-threatening obesity-related complications, currently receiving standard of care for them
trial access	unable to join an ongoing trial of retatrutide or a comparable investigational medicine, on eligibility grounds or because no enrolling site is reasonably accessible
prior discussion	all standard treatment options, bariatric surgery included, discussed with the patient
exclusion	a medical contraindication to the therapy

Reproduced from the registry record's own eligibility section, read 9 August 2026. The record lists no study locations.

What the opening was reported as: a BMJ news item in 2026 covered the same program under the heading of compassionate use. The registry record is the primary document, and it is the one the criteria above come from.

What that route is not: it is not a prescription, not a purchase, and not a category anything sold online falls into. Everything outside a trial and outside that record is the unapproved market the agency has been writing letters about.

Why does retatrutide appear in FDA databases at all?

Because listing and approval are separate acts, and the agency says so in plain words. Its page for the National Drug Code directory states that assignment of an NDC number does not in any way denote FDA approval of the product, and that inclusion in the directory does not indicate that FDA has verified the information provided.

What the twelve directory entries are: bulk ingredient filings from active pharmaceutical ingredient manufacturers, each with an empty application number. A bulk ingredient entry records that a company told the agency it makes the substance. It records nothing about whether any finished product may be sold.

What the ten DailyMed documents are: structured product labels from a single labeler, published on one day in November 2025. The one we opened declares its marketing category as export only, which is the filing category for product not intended for the domestic market, and it is written in the section shape used for over-the-counter medicines, with headings for uses, warnings and directions. A document formatted like a consumer label is still not an approval, and the paperwork that travels with unapproved material is worth reading with that in mind.

Where the agency has been explicit: its statement on unapproved GLP-1 drugs, current as of 15 June 2026, says that retatrutide and cagrilintide cannot be used in compounding under federal law, and that these are not components of FDA-approved drugs and have not been found safe and effective for any condition. The same statement records warnings issued to telehealth companies, to ingredient distributors and to outsourcing facilities.

Does a ClinicalTrials.gov entry mean the trial is real?

Not on its own, and this compound carries a working example of why. Thirty-two of the thirty-three retatrutide records name Eli Lilly and Company as sponsor. The thirty-third, NCT07467447, names a different sponsor, and its official title is byte-identical to the title of a genuine completed Lilly phase 2 trial, NCT04881760. We hashed both strings on 9 August 2026 and they match to the character. That record is named here only so it can be disavowed: it is not evidence and it is cited nowhere on this site, and while the raw count of thirty-three above includes it because that is what the registry returns, it counts toward no evidence claim on this page.

The second overlap: that record's organization study identifier is the string the genuine Lilly record lists among its own secondary identifiers, recorded there in the Lilly domain. The record was first posted on 12 March 2026, has not been updated since, lists a single site, and declares itself not to be an FDA-regulated drug study.

What this library does and does not say about it: the sponsor named on that record holds eight registry entries, and three of them describe themselves as examples or mock records inside their own summaries. This one does not, so we do not call it a fabrication and neither should anyone else. What we say is narrower and fully checkable: it reproduces a real trial's title and a real sponsor's protocol number, so it cannot carry evidential weight, and it is withdrawn from every citation surface on this site.

Why that belongs on a page about approval status: a reader checking whether the science behind a compound is real often lands on the register, and the register is a filing system rather than a verification service. Anyone counting retatrutide trials without opening them counts thirty-three. The number that survives reading them is thirty-two.

What the record leaves unanswered

Five gaps, and none of them closes before a submission exists:

The filing date. The first quarter of 2027 is a stated plan in a quarterly report, not a commitment anyone can hold the sponsor to.
The pathway. The sponsor names a Biologics License Application. Nothing we retrieved records the agency agreeing that this is the right route, and the two routes carry different exclusivity periods.
The indication and the exclusions. Both live on a label, and there is no label. Which populations end up named, and which end up named in a limitations of use section, is unsettled.
The long-term outcome data. The cardiovascular and kidney outcomes trial lists completion in February 2029, and the steatohepatitis master protocol runs to 2032. Those read out after any first approval, not before it.
Nine phase 3 records are still open. Five have completed. A program that has met its primary endpoints is not the same as a program that has finished.

The safety picture, as published

From the one phase 3 report in print: the frequent adverse events were gastrointestinal and generally mild to moderate, discontinuations for adverse events ran from 2 to 5 percent against 0 percent on placebo, no severe hypoglycaemia was reported, and two deaths occurred, both in one retatrutide group and both judged unrelated to the study drug.

From the agency, about the unapproved market: products of unknown quality, a warning to companies selling material falsely labeled for research purposes or not for human consumption while shipping it to people with dosing instructions, and complaints that injectable GLP-1 drugs requiring refrigeration have arrived warm. None of that is a picture of one person's risk, which is a question for a clinician with their history in front of them.

How this page is sourced

The queries are the spine: every database result printed above was run from this machine on 9 August 2026 against the named federal endpoint, and the HTTP status was recorded at the time. Where a result is an absence, a control query on an approved compound was run through the same endpoint in the same session.

Fourteen sources: two agency statements, one agency warning letter, two corporate filings to the SEC, four trial registry records, one drug labeling record, and four papers with DOIs and PubMed IDs.

What we could not settle: we found no retrievable agency document recording a decision on which application route retatrutide travels under, so the page reports the sponsor's stated intention and stops there. We also make no claim about any regulator outside the United States, because we could not get a working search out of the European Medicines Agency site on the day this was written, and an absence claim with no working instrument behind it is not evidence.

The standard: the full sourcing and citation-verification standard for this site, including who checks a page before it ships, lives on the methodology page.

Last reviewed: 9 August 2026.

1
U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of 15 June 2026. Read for the compounding position, the warnings issued to telehealth companies, ingredient distributors and outsourcing facilities, the refrigeration complaints, and the paragraph on product labeled for research purposes. Retrieved 9 August 2026, HTTP 200. fda.gov, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
2
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Warning letter to Gram Peptides, reference 721806, 31 March 2026, stating that products the firm offered for sale, retatrutide among them, are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355(a). Retrieved 9 August 2026, HTTP 200. fda.gov warning letter 721806.
3
U.S. Food and Drug Administration. National Drug Code Directory. Read for the statements that inclusion in the directory does not indicate that FDA has verified the information provided or that the products are FDA-approved, and that assignment of an NDC number does not in any way denote FDA approval of the product. Retrieved 9 August 2026, HTTP 200. fda.gov, National Drug Code Directory.
4
U.S. Food and Drug Administration, openFDA. Drugs@FDA and drug labeling endpoints queried for retatrutide as an active ingredient and as a substance name on 9 August 2026, both returning HTTP 404 with the body "No matches found!"; the National Drug Code endpoint queried for the same active ingredient returning HTTP 200 and twelve bulk ingredient entries; and the control query for tirzepatide returning HTTP 200 with NDA 215866 and NDA 217806. api.fda.gov, Drugs@FDA query for retatrutide.
5
National Library of Medicine, DailyMed. SALKALLI (retatrutide pen 30mg) injection, solution. Structured product label published 17 November 2025, set id 42d6e93c-7d91-e8ec-e063-6294a90a567f, read for its marketing category of export only and its section structure. One of ten retatrutide labels returned by a DailyMed name search on 9 August 2026, all from the same labeler. Retrieved 9 August 2026, HTTP 200. DailyMed, set id 42d6e93c-7d91-e8ec-e063-6294a90a567f.
6
Eli Lilly and Company. Second-quarter 2026 results, furnished to the U.S. Securities and Exchange Commission on Form 8-K, accession 0000059478-26-000077. Read for the statement that the retatrutide clinical data package is complete to support global registrations for obesity, obstructive sleep apnea and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027. Retrieved 9 August 2026, HTTP 200. sec.gov, Eli Lilly Form 8-K, second quarter 2026.
7
Eli Lilly and Company. Quarterly report on Form 10-Q for the period ended 30 June 2026, filed 5 August 2026, accession 0000059478-26-000081. Read for the clinical development pipeline update recording that phase 3 trials for retatrutide in obesity met their primary endpoints and that a phase 3 trial in type 2 diabetes met its primary endpoint. Retrieved 9 August 2026, HTTP 200. sec.gov, Eli Lilly Form 10-Q, 30 June 2026.
8
ClinicalTrials.gov. Pre-approval Expanded Access of Retatrutide (LY3437943), NCT07629401, Eli Lilly and Company, individual expanded access, overall status available, first posted 5 June 2026, last update posted 6 August 2026. Read for the brief summary and the full eligibility section reproduced above. Retrieved 9 August 2026, HTTP 200. ClinicalTrials.gov, NCT07629401.
9
ClinicalTrials.gov version 2 API. Intervention search for retatrutide run 9 August 2026, HTTP 200, returning a total count of 33 records: 14 phase 1, 4 phase 2, 14 phase 3 and 1 expanded access, with 32 sponsored by Eli Lilly and Company. Phase 3 status and enrollment counts in the table above were derived from the same response. ClinicalTrials.gov API, intervention search for retatrutide.
10
ClinicalTrials.gov. NCT04881760, sponsor Eli Lilly and Company, organization study id 18122, completed, the genuine phase 2 record discussed above. Retrieved 9 August 2026, HTTP 200. Its official title and the secondary identifier it records in the Eli Lilly and Company domain were compared by SHA-256 hash against the withdrawn record named in the body of this page, which this library does not cite as a source. ClinicalTrials.gov, NCT04881760.
11
Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. doi:10.1111/dom.70209. PMID 41090431.
12
Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. doi:10.1016/S0140-6736(26)00967-0. PMID 42250575.
13
Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PMID 37366315.
14
Brown C. Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it. BMJ. 2026;394:e100530. Cited only for the reporting that the program opened; the eligibility criteria on this page come from the registry record at reference 8. doi:10.1136/bmj-2026-100530. PMID 42567543.

Around this page: five neighboring pages on approval, classification, and what a vial can be shown to hold.

PT-141 and the Vyleesi approval: what an approval looks like once one exists, section by section.
Is MK-677 a SARM: the same question one rung further down, for a molecule whose development stopped instead of continuing.
Tirzepatide against semaglutide: the two approved incretin products this one is measured against.
What a purity number does not tell you: why a certificate is not a specification.
How to read a COA: the document that stands in when there is no approved product.

One regulatory read a week: the filings and the register, pulled apart and posted to The Decadewise briefing.

The disclaimer

Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice. It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.